Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)

NCT01462578 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT01462578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)
Lead sponsor
Technische Universität Dresden
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
February 28, 2021
Enrollment
93 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelocytic leukemia, myelodysplastic syndrome